154 related articles for article (PubMed ID: 11672916)
21. VaxArray for hemagglutinin and neuraminidase potency testing of influenza vaccines.
Kuck LR; Byrne-Nash R; Gillis J; Bueter K; Couzens LK; Eichelberger MC; Rowlen KL
Vaccine; 2018 May; 36(21):2937-2945. PubMed ID: 29699789
[TBL] [Abstract][Full Text] [Related]
22. Multi-subtype influenza virus-like particles incorporated with flagellin and granulocyte-macrophage colony-stimulating factor for vaccine design.
Liu WC; Liu YY; Chen TH; Liu CC; Jan JT; Wu SC
Antiviral Res; 2016 Sep; 133():110-8. PubMed ID: 27491439
[TBL] [Abstract][Full Text] [Related]
23. Mechanisms of broad cross-protection provided by influenza virus infection and their application to vaccines.
Tamura S; Tanimoto T; Kurata T
Jpn J Infect Dis; 2005 Aug; 58(4):195-207. PubMed ID: 16116250
[TBL] [Abstract][Full Text] [Related]
24. Protection of pigs against pandemic swine origin H1N1 influenza A virus infection by hemagglutinin- or neuraminidase-expressing attenuated pseudorabies virus recombinants.
Klingbeil K; Lange E; Blohm U; Teifke JP; Mettenleiter TC; Fuchs W
Virus Res; 2015 Mar; 199():20-30. PubMed ID: 25599604
[TBL] [Abstract][Full Text] [Related]
25. Antibody response to influenza vaccination in healthy adults.
Brydak LB; Tadeusz S; Magdalena M
Viral Immunol; 2004; 17(4):609-15. PubMed ID: 15671759
[TBL] [Abstract][Full Text] [Related]
26. Supplementation of conventional trivalent influenza vaccine with purified viral N1 and N2 neuraminidases induces a balanced immune response without antigenic competition.
Johansson BE; Pokorny BA; Tiso VA
Vaccine; 2002 Feb; 20(11-12):1670-4. PubMed ID: 11858877
[TBL] [Abstract][Full Text] [Related]
27. Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge.
Galarza JM; Latham T; Cupo A
Viral Immunol; 2005; 18(1):244-51. PubMed ID: 15802970
[TBL] [Abstract][Full Text] [Related]
28. Protection abilities of influenza B virus DNA vaccines expressing hemagglutinin, neuraminidase, or both in mice.
Fang F; Cai XQ; Chang HY; Wang HD; Yang ZD; Chen Z
Acta Virol; 2008; 52(2):107-12. PubMed ID: 18564897
[TBL] [Abstract][Full Text] [Related]
29. Virus-like particle vaccine conferred complete protection against a lethal influenza virus challenge.
Galarza JM; Latham T; Cupo A
Viral Immunol; 2005; 18(2):365-72. PubMed ID: 16035948
[TBL] [Abstract][Full Text] [Related]
30. Changing perspective on immunization against influenza.
Johansson BE; Brett IC
Vaccine; 2007 Apr; 25(16):3062-5. PubMed ID: 17276554
[TBL] [Abstract][Full Text] [Related]
31. Persistence of Antibodies to Influenza Hemagglutinin and Neuraminidase Following One or Two Years of Influenza Vaccination.
Petrie JG; Ohmit SE; Johnson E; Truscon R; Monto AS
J Infect Dis; 2015 Dec; 212(12):1914-22. PubMed ID: 26014800
[TBL] [Abstract][Full Text] [Related]
32. Incorporation of conserved nucleoprotein into influenza virus-like particles could provoke a broad protective immune response in BALB/c mice and chickens.
Xue C; Tian G; Chen X; Liu Q; Ma J; Xu S; Li X; Chen H; Cao Y
Virus Res; 2015 Jan; 195():35-42. PubMed ID: 25312452
[TBL] [Abstract][Full Text] [Related]
33. Neuraminidase, the Forgotten Surface Antigen, Emerges as an Influenza Vaccine Target for Broadened Protection.
Eichelberger MC; Monto AS
J Infect Dis; 2019 Apr; 219(Suppl_1):S75-S80. PubMed ID: 30715357
[TBL] [Abstract][Full Text] [Related]
34. Contribution of antibody production against neuraminidase to the protection afforded by influenza vaccines.
Marcelin G; Sandbulte MR; Webby RJ
Rev Med Virol; 2012 Jul; 22(4):267-79. PubMed ID: 22438243
[TBL] [Abstract][Full Text] [Related]
35. Squalene-containing licensed adjuvants enhance strain-specific antibody responses against the influenza hemagglutinin and induce subtype-specific antibodies against the neuraminidase.
Schmidt R; Holznagel E; Neumann B; Alex N; Sawatsky B; Enkirch T; Pfeffermann K; Kruip C; von Messling V; Wagner R
Vaccine; 2016 Oct; 34(44):5329-5335. PubMed ID: 27616472
[TBL] [Abstract][Full Text] [Related]
36. Quantitative analyses of all influenza type A viral hemagglutinins and neuraminidases using universal antibodies in simple slot blot assays.
Gravel C; Li C; Wang J; Hashem AM; Jaentschke B; Van Domselaar G; He R; Li X
J Vis Exp; 2011 Apr; (50):. PubMed ID: 21490585
[TBL] [Abstract][Full Text] [Related]
37. Hemagglutinin and Neuraminidase Antibodies Are Induced in an Age- and Subtype-Dependent Manner after Influenza Virus Infection.
Wong SS; Waite B; Ralston J; Wood T; Reynolds GE; Seeds R; Newbern EC; Thompson MG; Huang QS; Webby RJ;
J Virol; 2020 Mar; 94(7):. PubMed ID: 31941786
[TBL] [Abstract][Full Text] [Related]
38. Antibodies Directed toward Neuraminidase N1 Control Disease in a Mouse Model of Influenza.
Job ER; Schotsaert M; Ibañez LI; Smet A; Ysenbaert T; Roose K; Dai M; de Haan CAM; Kleanthous H; Vogel TU; Saelens X
J Virol; 2018 Feb; 92(4):. PubMed ID: 29167342
[TBL] [Abstract][Full Text] [Related]
39. Immunization with purified N1 and N2 influenza virus neuraminidases demonstrates cross-reactivity without antigenic competition.
Johansson BE; Kilbourne ED
Proc Natl Acad Sci U S A; 1994 Mar; 91(6):2358-61. PubMed ID: 8134399
[TBL] [Abstract][Full Text] [Related]
40. Inactivated H7 Influenza Virus Vaccines Protect Mice despite Inducing Only Low Levels of Neutralizing Antibodies.
Kamal RP; Blanchfield K; Belser JA; Music N; Tzeng WP; Holiday C; Burroughs A; Sun X; Maines TR; Levine MZ; York IA
J Virol; 2017 Oct; 91(20):. PubMed ID: 28768855
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
